A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye condition affecting central vision (what one sees straight ahead). The purpose of this study is to evaluate the progression rate of Geographic Atrophy in eyes of patients treated with cemdisiran alone or in combination with pozelimab compared to those treated with placebo. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug(s) * How much study drug(s) are in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)

NCT Number	NCT06541704
Lead Sponsor	Regeneron Pharmaceuticals
Conditions	Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
Enrollment	975 participants
Start Date	2024-10-30
Primary Completion	2028-07-31 (estimated)
Study Completion	2033-04-09 (estimated)
Updated on ClinicalTrials.gov	2026-08-11